Search research publications and outputs

  1. 2019
  2. The putative tumour suppressor protein Latexin is secreted by prostate luminal cells and is downregulated in malignancy

    Seed, R. I., Taurozzi, A. J., Wilcock, D. J., Nappo, G., Erb, H. H. H., Read, M. L., Gurney, M., Archer, L. K., Ito, S., Rumsby, M. G., Petrie, J. L., Clayton, A., Maitland, N. J. & Collins, A. T., 26 Mar 2019

    Article in Scientific Reports

  3. 2018
  4. KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice.

    Polson, ES., Kuchler, VB., Abbosh, C., Ross, EM., Mathew, RK., Beard, HA., da Silva, B., Holding, AN., Ballereau, S., Chuntharpursat-Bon, E., Williams, J., Griffiths, HBS., Shao, H., Patel, A., Davies, AJ., Droop, A., Chumas, P., Short, SC., Lorger, M., Gestwicki, JE. & 6 othersRoberts, LD., Bon, RS., Allison, SJ., Zhu, S., Markowetz, F. & Wurdak, H., 15 Aug 2018

    Article in Science Translational Medicine

  5. 2017
  6. 2016
  7. Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow

    Miftakhova, R., Hedblom, A., Semenas, J., Robinson, B. D., Simoulis, A., Malm, J., Rizvanov, A., David Heery, D., Mongan, N. P., Maitland, N. J., Allegrucci, C. & Persson, J. L., 15 Apr 2016

    Article in Cancer research

  8. An epigenetic reprogramming strategy to re-sensitize radioresistant prostate cancer cells

    Peitzsch, C., Cojoc, M., Hein, L., Kurth, I., Mӓbert, K., Trautmann, F., Klink, B., Schrock, E., Wirth, M. P., Krause, M., Stakhovsky, E. A., Telegeev, G. D., Novotny, V., Toma, M. I., Muders, M., Baretton, G. B., Frame, F. M., Maitland, N. J., Baumann, M. & Dubrovska, A., 16 Mar 2016

    Article in Cancer research

  9. 2015
  10. miR-25 modulates invasiveness and dissemination of human prostate cancer cells via regulation of αv- and α6 integrin expression

    Zoni, E., van der Horst, G., van de Merbel, A. F., Chen, L., Rane, J. K., Pelger, R. C. M., Collins, A. T., Visakorpi, T., Snaar-Jagalska, B. E., Maitland, N. J. & van der Pluijm, G., 1 Jun 2015

    Article in Cancer research

  11. CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations

    Khanna, A., Rane, J. K., Kivinummi, K. K., Urbanucci, A., Helenius, M. A., Tolonen, T. T., Saramäki, O. R., Latonen, L., Manni, V., Pimanda, J. E., Maitland, N. J., Westermarck, J. & Visakorpi, T., 19 Apr 2015

    Article in Oncotarget

  12. Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy

    Santer, F. R., Erb, H. H. H., Oh, S. J., Handle, F., Feiersinger, G. E., Luef, B., Bu, H., Schäfer, G., Ploner, C., Egger, M., Rane, J. K., Maitland, N. J., Klocker, H., Eder, I. E. & Culig, Z., 20 Mar 2015

    Article in Oncotarget

Previous 1 2 3 4 5 6 7 Next